Surufatinib

Generic Name: Surufatinib

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₈N_₆O_₃S

CAS Number: 1308672-74-3

Unique Ingredient Identifier: B2K5L1L8S9

Background: Surufatinib is under investigation in clinical trial NCT02588170 (Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors).

Indication: 单药用于治疗无法手术切除的局部晚期或转移性、进展期非功能性、分化良好（G1、G2）的胰腺和非胰腺来源的神经内分泌瘤（pNETs）。

Clinical Trials

Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors

Phase 2

Not yet recruiting

Conditions: Unresectable Advanced Solid Tumors
Biliary Tract Tumors, Gastric Cancer, Small Cell Lung Cancer

Interventions: Drug: Surufatinib
Drug: Sintilimab
Radiation: Short course radiotherapy

First Posted Date: 2022-09-06

Last Posted Date: 2022-09-06

Lead Sponsor: Wuhan Union Hospital, China

Target Recruit Count: 36

Registration Number: NCT05527821

Locations: 🇨🇳
Union hospital, Wuhan, Hubei, China

Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Extensive-Stage Small Cell Lung Cancer

Interventions: Drug: Anti-PD-1/L1
Drug: Surufatinib

First Posted Date: 2022-08-22

Last Posted Date: 2023-03-13

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 60

Registration Number: NCT05509699

Locations: 🇨🇳
Chinese PLA General Hospital, Beijing, China

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Phase 1

Recruiting

Conditions: Ovarian Cancer
Primary Peritoneal Cancer
Ovarian Carcinoma
Fallopian Tube Carcinosarcoma
Platinum-resistant Ovarian Cancer

Interventions: Drug: Pamiparib
Drug: Surufatinib

First Posted Date: 2022-08-10

Last Posted Date: 2023-04-11

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 38

Registration Number: NCT05494580

Locations: 🇨🇳
Sun Yat-sen University Cancer Cetntre, Guangzhou, China

Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer

Phase 2

Recruiting

Conditions: Pancreatic Neoplasms

Interventions: Drug: Surufatinib
Drug: TAS-102

First Posted Date: 2022-08-01

Last Posted Date: 2023-11-13

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 20

Registration Number: NCT05481463

Locations: 🇨🇳
Cancer center of SunYat-sen University, Guangzhou, Guangdong, China

Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase 2

Recruiting

Conditions: Pancreatic Neoplasms

Interventions: Drug: Surufatinib
Drug: Sintilimab
Drug: AG

First Posted Date: 2022-08-01

Last Posted Date: 2023-08-09

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 32

Registration Number: NCT05481476

Locations: 🇨🇳
Cancer center of SunYat-sen University, Guangzhou, Guangdong, China

Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma

Phase 2

Recruiting

Conditions: Adenocarcinoma of Small Intestine
Metastatic
Appendix Carcinoma

Interventions: Drug: Surufatinib
Drug: Sintilimab
Drug: Capecitabine

First Posted Date: 2022-07-25

Last Posted Date: 2023-02-28

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 36

Registration Number: NCT05472948

Locations: 🇨🇳
The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Surufatinib With or Wothout Immunotherapy for Advanced Colorectal Cancer in Later Line

Phase 2

Recruiting

Conditions: Colorectal Neoplasms

First Posted Date: 2022-05-12

Last Posted Date: 2022-11-09

Lead Sponsor: Hubei Cancer Hospital

Target Recruit Count: 50

Registration Number: NCT05372198

Locations: 🇨🇳
Hubei Cancer Hospital, Wuhan, Hubei, China

Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma; Targeted Therapy; Progression-free Survival

Interventions: Drug: Surufatinib

First Posted Date: 2022-03-16

Last Posted Date: 2022-03-16

Lead Sponsor: Zhongnan Hospital

Target Recruit Count: 45

Registration Number: NCT05282433

Locations: 🇨🇳
Zhongnan Hopital of Wuhan University, Wuhan, Hubei, China

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

Phase 1

Recruiting

Conditions: Pancreatic Cancer
PDAC - Pancreatic Ductal Adenocarcinoma
Pancreas Cancer
Pancreatic Neoplasms

Interventions: Drug: surufatinib + camrelizumab + nab-paclitaxel + S-1
Drug: nab-paclitaxel + gemcitabine

First Posted Date: 2022-02-01

Last Posted Date: 2024-12-31

Lead Sponsor: Chinese PLA General Hospital

Target Recruit Count: 90

Registration Number: NCT05218889

Locations: 🇨🇳
Chinese PLA General Hospital, Beijing, China

An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer

Phase 2

Recruiting

Conditions: Breast Cancer
Breast Cancer Female

Interventions: Drug: surufatinib + fulvestrant + chidamide

First Posted Date: 2022-01-11

Last Posted Date: 2022-09-02

Lead Sponsor: The First Affiliated Hospital of Zhengzhou University

Target Recruit Count: 63

Registration Number: NCT05186545

Locations: 🇨🇳
Anyang Tumor Hospital, Anyang, China
🇨🇳
Nanyang Second General Hospital, Nanyang, China
🇨🇳
Henan University of Science and Technology First Affiliated Hospital, Luoyang, China

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy